Jon Faldasz: Ondansetron May Have Cardiotoxicity Risk Among 5-HT3RAs Due to High Concentration in Cardiac Tissues
Jon Faldasz, Senior Director of Product and Customer Experience at InsightRX, posted on LinkedIn:
”Just dropped: Ondansetron may have outstanding cardiotoxicity risk among 5-HT3RAs due to high concentration in cardiac tissues
Published today in Nature Scientific Reports, Cai et al used the FDA’s Adverse Event Reporting System (FAERS) to review records of cardiotoxicity associated with 5-HT3RA use. They found:
– The different 5-HT3RAs exhibit varying degrees and types of cardiotoxicity
– QT prolongation was most common for ondansetron (granisetron was least common)
– In a subsequent PBPK model extrapolation they estimated that ondansetron concentrations in cardiac tissue were 2.3x higher than plasma.
They suggested that providers might “prioritize low cardiac toxicity 5-HT3RAs” (read: avoid ondansetron) in patients with heart disease.
For my part, FAERS seems like an untapped resource for this type of work, now I’m thinking on what other investigations could make use of it.
Article reference here.”
Title: Cardiotoxicity of different 5-HT3 receptor antagonists analyzed using the FAERS database and pharmacokinetic study
Authors: Yijun Cai, Shaohong Luo, Shen Lin, Xiaoting Huang, Xiangzhen Wang, Lijing Yang, Xiongwei Xu, Xiuhua Weng
Stay updated with Hemostasis Today.
-
Oct 10, 2026, 00:34Raphaëlle Dodart: Discussing the Mechanisms of Menstrual Hemostasis
-
Oct 10, 2026, 00:26Barbara Adams Krolak: Discussing the Growing Need for Blood Clot Prevention in Asia
-
Oct 9, 2026, 23:59Ana Pedrero Gil: Is Coagulopathy with Fibrinolysis Present in All Obstetric Hemorrhages?
-
Oct 9, 2026, 23:57Exploring the Psychosocial Needs of People with Bleeding Disorders in Kyrgyzstan – EAHAD
-
Oct 9, 2026, 23:53Bernard Slater Jr.: Serving on the Advisory Council for the NBDF West Virginia Chapter
-
Oct 9, 2026, 23:53Aurelio Maggio: Thalassemia Reports Real-Time Impact Factor Rises to 1.760
-
Oct 9, 2026, 23:52Stronger Connections, Stronger Organizations – World Federation of Hemophilia
-
Oct 9, 2026, 23:46Samuel Misiani Mbunya: Advancing Sickle Cell Care Through Collaboration at the 21st ASCAT Conference
-
Oct 9, 2026, 23:42Hadeel Swed: My First First-Author Publication in Thrombosis Research